Dr. Kohli On The Use Of Enzalutamide And Apalutamide In Mhspc

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Dr. Kohli on Sequencing Concerns in Metastatic Hormone-Sensitive Prostate Cancer

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

Dr. Azad on the Benefit of Adding Enzalutamide to ADT in mHSPC

Dr. Kohli Discusses Ongoing Correlative Science in Prostate Cancer

Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer

Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC

GU Oncology Now

Dr. Agarwal on the QoL With Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

PARP inhibitors for metastatic hormone sensitive prostate cancer

Role of the addition of docetaxel to ADT in mHSPC

Enzalutamide for Biochemically Recurrent Prostate Cancer | NEJM

Apalutamide for High-Risk Prostate Cancer | Learn About Clinical Trials

Prostate Cancer Research Institute

The evolving standard of care for patients with metastatic hormone-sensitive prostate cancer

PANTHER: apalutamide + abiraterone in Black and White mCRPC patients

Considerations for Apalutamide Versus Enzalutamide in Prostate Cancer Treatment

Specialty Pharmacy Times

Real-world PSA responses to apalutamide or enzalutamide in mCSPC

Dr. Saad on the Clinical Impact of Apalutamide in nmCRPC

Awaiting key results for enzalutamide and apalutamide in nmCRPC

Tomasz Beer, MD Speaks On Xtandi, Erleada, & Nubeqa | Excerpt from the 2019 PCRI Conference

Prostate Cancer Research Institute